| Type : | Industriel |
| Statut : | Ouvert |
| Phase : | Étude observationnelle |
| Étape du traitement : | Traitements combinés |
| Date d'ouverture : | 01/07/2022 |
| Date clôture : | 30/11/2025 |
| Promoteur : | Ipsen |
| Progression du cancer: | Pas de progression |
Résumé :
The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-component, according to real-world clinical practice. The decision to prescribe cabozantinib and nivolumab in combination will be made prior to, and independently from, the decision to enrol the participant in study.
Domaines/spécialités :
- Cancers uro-génitaux
- Rein
Pathologies :
- Tumeur maligne du rein, à l'exception du bassinet - Cim10 : C64
Liens externes :